The NEW DAY study evaluating Iluvien for diabetic macular edema did not meet its primary endpoint, but showed favorable ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

Neovascular age-related macular degeneration (nAMD) is a progressive eye disease characterized by choroidal ...

North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence ...

D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for ...

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.

Detailed price information for 4D Molecular Therapeutics Inc (FDMT-Q) from The Globe and Mail including charting and trades.

The share price of Shilpa Medicare (NSE: SHILPAMED) closed at Rs 909.90 on August 14, 2025, representing a slight increase of ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

Zydus Lifesciences Limited has announced its unaudited consolidated financial results for the first quarter ended June 30, ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...